NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00991211,Bendamustine Plus Rituximab Versus CHOP Plus Rituximab,https://clinicaltrials.gov/study/NCT00991211,,COMPLETED,The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival (PFS).,NO,Non-Hodgkin Lymphomas|Follicular Lymphomas|Immunocytomas|Lymphocytic Lymphomas|Marginal Zone Lymphomas,DRUG: Bendamustine|DRUG: Standard chemotherapy CHOP + Ritiximab,"Progression free survival, observation 3 years or significant differences between two arms","Determination and comparison of remission rates, of toxicity, infectious complications, overall survival, EFS, TTNT, capacity of peripheral blood stem cell mobilization, ongoing",,University of Giessen,,ALL,"ADULT, OLDER_ADULT",PHASE3,549,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,NHL 1-2003,2004-01,2009-08,2009-08,2009-10-07,,2024-08-22,"StiL Head Office; Justus-Liebig-University, Giessen, 35392, Germany",
